Physician profile
Subhashish Pal
NPI 1386753952
$1,265.01
in general payments reported to CMS, 2019-2025
10 companies · $394 in 2025
The $394 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $184 · 2021: $67.93 · 2022: $45.03 · 2023: $325 · 2024: $249 · 2025: $394.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $968.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $967.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $336.96 | 2020-2023 | Farxiga, Brilinta |
| E.R. Squibb & Sons, L.L.C. | $208.39 | 2023-2024 | Camzyos |
| Abiomed | $187.02 | 2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $174.86 | 2025 | Lifevest |
| Heartflow, INC. | $148.71 | 2024-2025 | |
| Abbott Laboratories | $112.96 | 2021-2022 | |
| Boston Scientific Corporation | $33.57 | 2020-2024 | Watchman Flx |
| Cardiovascular Systems INC. | $23.93 | 2020 | |
| Irhythm Technologies, INC. | $20.07 | 2020 | |
| Lantheus Medical Imaging, INC. | $18.54 | 2023 | Definity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Subhashish Pal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.